7. Inviting women to screening programmes
For inviting women to subsequent breast cancer screening rounds, the ECIBC's Guidelines Development Group (GDG):
- recommends using a letter (strong recommendation, moderate certainty of the evidence)
- suggests using a letter with a fixed appointment time (conditional recommendation, moderate certainty of the evidence)
- suggests using a letter with a General Practitioner's (GP) signature (conditional recommendation, high certainty of the evidence)
- suggests using a letter followed by a phone call to remind (conditional recommendation, moderate certainty of the evidence)
- suggests using a letter followed by a written reminder (conditional recommendation, moderate certainty of the evidence)
- suggests not using a letter followed by a face to face intervention (conditional recommendation, low certainty of the evidence)
Inviting women to subsequent screening rounds: letter followed by face to face intervention vs. letter
Issued on: June 2018
Healthcare question
Should a letter followed by a face to face intervention vs. a letter alone be used for inviting women to subsequent breast cancer screening rounds?
Recommendation
The ECIBC's Guidelines Development Group (GDG) suggests not using a letter followed by a face to face intervention for inviting women to subsequent breast cancer screening rounds.
Recommendation strength
| Conditional recommendation |
| Low certainty of the evidence |
Justification
The GDG made a conditional recommendation against the intervention and the judgement was based mainly on the imprecise estimates of the desirable effects and the large costs that were anticipated. The GDG did not think this intervention was feasible to implement in jurisdictions where it is not already being used.
Subgroup considerations
The GDG noted that for the subgroup of women who had a false positive results in the previous screening round the intervention may be feasible and the cost are decreased (moderate) because of the smaller number of women involved. Moreover in this subgroup it is expected to have a larger effect (due to probably higher prevalence).
For these reasons the GDG suggests for inviting women who had a false positive result in the previous screening round to the subsequent ones using a letter followed by a face to face interviention (conditional recommendation, low certainty of the evidence).
Considerations for implementation and policy making
- The comparison evaluated for this recommendation needs to be interpreted in the context of the other comparisons on methods for inviting women to screening programmes evaluated by ECIBC.
- The GDG was not aware of any countries currently using face-to-face invitation in addition to letters for invitation to screening programmes.
- The GDG judged that the intervention was not feasible to implement, given the monetary costs. For the subgroup of women who tested false positive in a previous screening round the intervention should be more feasible and the costs should be lower due to the smaller number of women involved.
- Most of the EU programmes involved in a survey about the way of communicating results of breast cancer screening reported that they do not differentiate between women who tested negative in the previous screening round and women who were false positive. Women are invited in the same way with identical invitation letters.
Supporting material
- Organised vs. non-organised screening
- Double vs. single reading in mammograpy screening
- Communication skills training
- Communication with care providers
- Optimal number of mammography readings
- Specialised training
- Risk stratification
- Women aged 40-44: screening vs. no screening
- Women aged 45-49: screening vs. no screening
- Women aged 45-49: annual vs. biennial screening
- Women aged 45-49: annual vs. triennial screening
- Women aged 45-49: triennial vs. biennial screening
- Women aged 50-69: screening vs. no screening
- Women aged 50-69: annual vs. biennial screening
- Women aged 50-69: annual vs. triennial screening
- Women aged 50-69: triennial vs. biennial screening
- Women aged 70-74: screening vs. no screening
- Women aged 70-74: annual vs. biennial screening
- Women aged 70-74: annual vs. triennial screening
- Women aged 70-74: triennial vs. biennial screening
- Single reading with AI support
- Double reading with AI support
- Screening with tomosynthesis vs. mammography
- Screening with tomosynthesis plus mammography vs. mammography alone
- Tailored screening with tomosynthesis
- Screening with tomosynthesis vs. mammography
- Tailored screening with MRI
- Tailored screening with ABUS
- Tailored screening with HHUS
- Informing about benefits and harms: use of decision aids
- Informing about benefits and harms: Numbers in addition to plain language
- Informing about benefits and harms: Infographics in addition to plain language
- Informing about benefits and harms: Story telling in addition to plain language
- Inviting women to screening: letter vs. no invitation
- Inviting socially disadvantaged women to screening: Targeted vs. general communication strategy
- Inviting women with an intellectual disability to screening
- Inviting non-native speakers to screening
- Inviting socially disadvantaged women to screening: Tailored vs. targeted communication strategy
- Inviting socially disadvantaged women to screening: Tailored vs. general communication strategy
- Inviting women to subsequent screening rounds: letter vs. no invitation
- Inviting women to screening: letter with fixed appointment vs. letter
- Inviting women to subsequent screening rounds: letter with fixed appointment vs. lett
- Inviting women to screening: letter with GP signature vs. letter
- Inviting women to subsequent screening rounds: letter with GP signature vs. letter
- Inviting women to screening: letter followed by phone call vs. letter
- Inviting women to subsequent screening rounds: letter followed by phone call vs. letter
- Inviting women to screening: letter followed by phone call vs. no invitation
- Inviting women to screening: letter followed by written reminder vs. letter
- Inviting women to subsequent screening rounds: letter followed by written reminder vs. letter
- Inviting women to screening: letter followed by face to face intervention vs. letter
- Inviting women to subsequent screening rounds: letter followed by face to face intervention vs. letter
- Inviting women to screening: e-mail vs. letter
- Inviting women to screening: automated telephone call vs. letter
- Inviting women to screening: letter followed by automated telephone call vs. letter
- Inviting women to screening: letter followed by SMS notification vs. letter
- Inviting women to screening: letter followed by personalised phone call vs. automated phone call
- Negative result: letter vs. nothing
- Further assessment: letter followed by a phone call
- Further assessment: timing of results
- Negative result: phone call vs. letter
- Negative result: face to face interview vs. letter
- Negative result: timing of results
- Tomosynthesis vs. assessment mammography
- Obtaining a sample from a suspicious breast lesion
- Type of guidance for needle core biopsy
- Stage 1: conventional exams
- Stage 1: PET-CT exams
- Stage 2: conventional exams
- Stage 2: PET-CT exams
- Stage 3: conventional exams
- Stage 3: PET-CT exams
- Stage 3: conventional exams plus PET-CT
- Use of clip-marking
- Additional magnetic resonance imaging
- Contrast-enhanced mammography
- Threshold of oestrogen for endocrine therapy
- Threshold of progesterone for endocrine therapy
- Multigene testing: 70 gene signature at low clinical risk
- Multigene testing: 70 gene signature at high clinical risk
- Multigene testing: 21 gene recurrence score
- Organising screening programmes
- Risk stratification
- Women 40-44
- Women 45-49
- Women 50-69
- Women 70-74
- Women with high breast density
- General Population
- Vulnerable Population
- Informing women about their results
- Women recalled due to suspicious lesions
- Obtaining a sample from a suspicious lesion
- Type of guidance for needle core biopsy
- Stage 1
- Stage 2
- Stage 3
- Planning surgical treatment
- Hormone receptor to guide use of endocrine therapy
- Multigene testing to guide use of chemotherapy